Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy

PURPOSE: Regadenoson was approved for clinical use in Europe in 2011. Since then, it has become the default form of stress at our institution. We have assessed the side-effect profile and tolerability of regadenoson in patients undergoing clinically indicated myocardial perfusion scintigraphy betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Brinkert, M., Reyes, E., Walker, S., Latus, K., Maenhout, A., Mizumoto, R., Nkomo, C., Standbridge, K., Wechalekar, K., Underwood, S. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913852/
https://www.ncbi.nlm.nih.gov/pubmed/24265072
http://dx.doi.org/10.1007/s00259-013-2619-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913852/
https://www.ncbi.nlm.nih.gov/pubmed/24265072
http://dx.doi.org/10.1007/s00259-013-2619-0

Ejemplares similares